Dry and Wet Age-Related Macular Degeneration | TreatmentTrends | EU | 2015
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (EU) is the fourth annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and the competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists across the major European markets (EU5; France, Germany, Italy, Spain, and the United Kingdom) who personally administer anti-vascular endothelial growth factor (VEGF) injections. The report covers the current and anticipated use of intravitreal injections, in particular the anti-VEGF agents (i.e., Roche’s Avastin [bevacizumab], Bayer HealthCare’s Eylea [aflibercept], and Novartis’s Lucentis [ranibizumab]), in the treatment of wet AMD. We also assess surveyed physicians’ perceptions of these wet AMD products—e.g., their advantages and disadvantages, typical patient types, barriers to growth—and current detailing and messaging efforts for approved wet AMD brands. Respondents are asked about their awareness of products in development for geographic atrophy (GA) or wet AMD and anticipated integration of these products in the treatment algorithm, as well as the potential for biosimilars in the wet AMD market.
